<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39352932</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>41</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma.</ArticleTitle><Pagination><StartPage>e2414957121</StartPage><MedlinePgn>e2414957121</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2414957121</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2414957121</ELocationID><Abstract><AbstractText>In the Spring of 2020, the United States of America (USA) deployed COVID-19 convalescent plasma (CCP) to treat hospitalized patients. Over 500,000 patients were treated with CCP during the first year of the pandemic. In this study, we estimated the number of actual inpatient lives saved by CCP treatment in the United States of America based on CCP weekly use, weekly national mortality data, and CCP mortality reduction data from meta-analyses of randomized controlled trials and real-world data. We also estimate the potential number of lives saved if CCP had been deployed for 100% of hospitalized patients or used in 15 to 75% of outpatients. Depending on the assumptions modeled in stratified analyses, we estimated that CCP saved between 16,476 and 66,296 lives. The CCP ideal use might have saved as many as 234,869 lives and prevented 1,136,133 hospitalizations. CCP deployment was a successful strategy for ameliorating the impact of the COVID-19 pandemic in the USA. This experience has important implications for convalescent plasma use in future infectious disease emergencies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dragotakes</LastName><ForeName>Quigly</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, MD 21205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patrick W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL 32224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buras</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Clinical Trials, Department of Quantitative Health Sciences, Scottsdale, AZ 85259.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Rickey E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-0818-273X</Identifier><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joyner</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-7135-7643</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN 55905.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloch</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD 21205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebo</LastName><ForeName>Kelly A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD 21205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanley</LastName><ForeName>Daniel F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD 21205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Jeffrey P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0003-1755-3202</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, Louis, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirofski</LastName><ForeName>Liise-Anne</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Albert Einstein College of Medicine, New York, NY 10461.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoham</LastName><ForeName>Shmuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7276-7786</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD 21205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senefeld</LastName><ForeName>Jonathon W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Health and Kinesiology, University of Illinois Urbana-Champaign, Urbana, IL 61801.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tobian</LastName><ForeName>Aaron A R</ForeName><Initials>AAR</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD 21205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiggins</LastName><ForeName>Chad C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Kinesiology, Michigan State University, East Lansing, MI 48823.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>R Scott</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Departments of Cardiovascular Medicine and Human Research Protection Program, Mayo Clinic, Rochester, MN 55905.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paneth</LastName><ForeName>Nigel S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI 48823.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI 48823.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0003-0319-0578</Identifier><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, MD 21205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casadevall</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9402-9167</Identifier><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, MD 21205.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093522" MajorTopicYN="Y">COVID-19 Serotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">convalescent plasma</Keyword><Keyword MajorTopicYN="N">mortality</Keyword></KeywordList><CoiStatement>Competing interests statement:Klassen S.A., Senefeld J.W., Johnson P.W., Carter R.E., Wiggins C.C., Shoham S., Henderson J.P., Pirofski L.A., Wright R.S., Paneth N.S., Casadevall A., and Joyner M.J. and reviewers Musser J. and Hartmann W.R. were co-authors in a review/position paper dealing with the use of CCP published in 2021.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>3</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39352932</ArticleId><ArticleId IdType="pmc">PMC11474081</ArticleId><ArticleId IdType="doi">10.1073/pnas.2414957121</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Senefeld J. W., et al. , Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Med. 18, e1003872 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8730442</ArticleId><ArticleId IdType="pubmed">34928960</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner M. J., et al. , Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J. Clin. Invest. 130, 4791–4797 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456238</ArticleId><ArticleId IdType="pubmed">32525844</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner M. J., et al. , Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin. Proc. 95, 1888–1897 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7368917</ArticleId><ArticleId IdType="pubmed">32861333</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner M. J., et al. , Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three-month experience. medRxiv [Preprint]. 10.1101/2020.08.12.20169359 (Accessed 12 September 2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.12.20169359</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner M. J., et al. , Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl. J. Med. 384, 1015–1027 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821984</ArticleId><ArticleId IdType="pubmed">33523609</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A., et al. , Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife 10, e69866 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8205484</ArticleId><ArticleId IdType="pubmed">34085928</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A., et al. , Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 371, m3939 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578662</ArticleId><ArticleId IdType="pubmed">33093056</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonovich V. A., et al. , A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl. J. Med. 384, 619–629 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7722692</ArticleId><ArticleId IdType="pubmed">33232588</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymous, Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): A randomised controlled, open-label, platform trial. Lancet 397, 2049–2059 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121538</ArticleId><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Menichetti F., et al. , Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: A randomized clinical trial. JAMA Netw Open 4, e2136246 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8630572</ArticleId><ArticleId IdType="pubmed">34842924</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A., et al. , Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. Expert. Rev. Respir. Med. 17, 381–395 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37129285</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., et al. , COVID-19 convalescent plasma and clinical trials: Understanding conflicting outcomes. Clin. Microbiol. Rev. 35, e0020021 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491201</ArticleId><ArticleId IdType="pubmed">35262370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunze K. L., et al. , Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors. Nat. Commun. 12, 4864 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357797</ArticleId><ArticleId IdType="pubmed">34381030</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan D. J., et al. , Early outpatient treatment for Covid-19 with convalescent plasma. N Engl. J. Med. 386, 1700–1711 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006786</ArticleId><ArticleId IdType="pubmed">35353960</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine A. C., et al. , COVID-19 convalescent plasma outpatient therapy to prevent outpatient hospitalization: A meta-analysis of individual participant data from five randomized trials. Clin. Infect. Dis. 76, 2077–2086 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10273382</ArticleId><ArticleId IdType="pubmed">36809473</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson M. A., et al. , Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol. 7, 1167–1175 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8377563</ArticleId><ArticleId IdType="pubmed">34137799</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., McConnell S., Sullivan D. J., Casadevall A., Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment. Drug Resist. Updat. 71, 100991 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37572569</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld J. W., et al. , COVID-19 convalescent plasma for the treatment of immunocompromised patients: A systematic review and meta-analysis. JAMA Netw. Open 6, e2250647 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857047</ArticleId><ArticleId IdType="pubmed">36633846</ArticleId></ArticleIdList></Reference><Reference><Citation>González S. E., et al. , Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia. J. Investig. Med. 70, 1258–1264 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35135872</ArticleId></ArticleIdList></Reference><Reference><Citation>De Silvestro G., et al. , Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) registry. Eur. J. Intern. Med. 97, 42–49 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8710400</ArticleId><ArticleId IdType="pubmed">34980505</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold Egloff S. A., et al. , Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J. Clin. Invest. 131, e151788 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8516450</ArticleId><ArticleId IdType="pubmed">34464352</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar E., et al. , Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgG. Am. J. Pathol. 191, 90–107 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7609241</ArticleId><ArticleId IdType="pubmed">33157066</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld J. W., et al. , Rates among hospitalized patients with COVID-19 treated with convalescent plasma: A systematic review and meta-analysis. Mayo Clin. Proc. Innov. Qual. Outcomes 7, 499–513 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10582279</ArticleId><ArticleId IdType="pubmed">37859995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan D. J., et al. , Outpatient randomized controlled trials to reduce COVID-19 hospitalization: Systematic review and meta-analysis. J. Med. Virol. 95, e29310 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10754263</ArticleId><ArticleId IdType="pubmed">38105461</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R., Chen S., Gan E. S., Ooi E. E., Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine 55, 102768 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161485</ArticleId><ArticleId IdType="pubmed">32344202</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch E. M., et al. , How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?. Transfusion 62, 933–941 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9086144</ArticleId><ArticleId IdType="pubmed">35352362</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner M. J., et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin. Proc. 95, 1888–1897 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7368917</ArticleId><ArticleId IdType="pubmed">32861333</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster R., et al. , Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint] (2020). 10.1101/2020.11.20.20234013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.20.20234013</ArticleId></ArticleIdList></Reference><Reference><Citation>Huaman M. A., et al. , Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials. Transfusion 63, 1639–1648 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10720768</ArticleId><ArticleId IdType="pubmed">37534607</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster R., et al. , Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N. Engl. J. Med. 384, 610–618 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine A. C., et al. , Coronavirus Disease 2019 convalescent plasma outpatient therapy to prevent outpatient hospitalization: A meta-analysis of individual participant data from 5 randomized trials. Clin. Infect. Dis. 76, 2077–2086 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10273382</ArticleId><ArticleId IdType="pubmed">36809473</ArticleId></ArticleIdList></Reference><Reference><Citation>McCreary E. K., Escobar Z. K., Justo J. A., Monoclonal antibodies for the treatment of COVID-19-every day you fight like you’re running out of time. JAMA Netw Open 6, e239702 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37093604</ArticleId></ArticleIdList></Reference><Reference><Citation>French G., et al. , Impact of hospital strain on excess deaths during the COVID-19 pandemic-United States, July 2020-July 2021. Am. J. Transpl. 22, 654–657 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9811904</ArticleId><ArticleId IdType="pubmed">35113490</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsfeldt R. L., et al. , Inpatient hospital costs for COVID-19 patients in the United States. Adv. Ther. 38, 5557–5595 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491188</ArticleId><ArticleId IdType="pubmed">34609704</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchini M., et al. , Safety and efficacy of convalescent plasma combined with other pharmaceutical agents for treatment of COVID-19 in hospitalized patients: A systematic review and meta-analysis. Diseases 12, 41 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10969279</ArticleId><ArticleId IdType="pubmed">38534965</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal A., Eight fatal anaphylactic reactions to penicillin. N Y State J. Med. 54, 1485–1487 (1954).</Citation><ArticleIdList><ArticleId IdType="pubmed">13154645</ArticleId></ArticleIdList></Reference><Reference><Citation>Popovsky M. A., Moore S. B., Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 25, 573–577 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">4071603</ArticleId></ArticleIdList></Reference><Reference><Citation>Bux J., Transfusion-related acute lung injury (TRALI): A serious adverse event of blood transfusion. Vox Sang 89, 1–10 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15938734</ArticleId></ArticleIdList></Reference><Reference><Citation>Webert K. E., Blajchman M. A., Transfusion-related acute lung injury. Curr. Opin. Hematol. 12, 480–487 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16217166</ArticleId></ArticleIdList></Reference><Reference><Citation>Arya R. C., Wander G., Gupta P., Blood component therapy: Which, when and how much. J. Anaesthesiol. Clin. Pharmacol. 27, 278–284 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3127320</ArticleId><ArticleId IdType="pubmed">21772701</ArticleId></ArticleIdList></Reference><Reference><Citation>Amrutiya V., et al. , Transfusion-related acute lung injury in a COVID-19-positive convalescent plasma recipient: A case report. J. Int. Med. Res. 49, 3000605211032814 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381434</ArticleId><ArticleId IdType="pubmed">34412545</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll T. D., et al. , Vaccine-boosted CCP decreases virus replication and hastens resolution of infection despite transiently enhancing disease in SARS-CoV-2-infected hamsters. J. Infect. Dis. 229, 1702–1710 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11175670</ArticleId><ArticleId IdType="pubmed">38213276</ArticleId></ArticleIdList></Reference><Reference><Citation>Haagmans L., et al. , SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model. J. Infect. Dis. 223, 2020–2028 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8243397</ArticleId><ArticleId IdType="pubmed">34043806</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamatsu Y., et al. , Highly neutralizing COVID-19 convalescent plasmas potently block SARS-CoV-2 replication and pneumonia in Syrian hamsters. J. Virol. 96, e01551–e01521 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865546</ArticleId><ArticleId IdType="pubmed">34818068</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rompay K. K. A., et al. , Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation. PLoS Pathog. 18, e1009925 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9060337</ArticleId><ArticleId IdType="pubmed">35443018</ArticleId></ArticleIdList></Reference><Reference><Citation>Deere J. D., et al. , SARS-CoV-2 infection of rhesus macaques treated early with human COVID-19 convalescent plasma. Microbiol. Spectr. 9, e0139721 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8612156</ArticleId><ArticleId IdType="pubmed">34817208</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconato M., et al. , Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. J. Clin. Invest. 132, e158190 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197521</ArticleId><ArticleId IdType="pubmed">35482408</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias K. M., et al. , Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: A systematic review and meta-analysis. Lancet. Microbe. 5, e459–e467 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38583464</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill A. B., The environment and disease: Association or causation? Proc. R Soc. Med. 58, 295–300 (1965).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1898525</ArticleId><ArticleId IdType="pubmed">14283879</ArticleId></ArticleIdList></Reference><Reference><Citation>Begin P., et al. , Convalescent plasma for hospitalized patients with COVID-19: An open-label, randomized controlled trial. Nat. Med. 27, 2012–2024 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8604729</ArticleId><ArticleId IdType="pubmed">34504336</ArticleId></ArticleIdList></Reference><Reference><Citation>Maor Y., et al. , Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine 26, 100525 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7480446</ArticleId><ArticleId IdType="pubmed">32923991</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H. S., et al. , Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial. JCI Insight. 9, e178460 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11141865</ArticleId><ArticleId IdType="pubmed">38483534</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H., et al. , Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation. BMC Infect. Dis. 24, 639 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11201301</ArticleId><ArticleId IdType="pubmed">38926676</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar K. J., et al. , A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J. Clin. Invest. 131, e155114 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670841</ArticleId><ArticleId IdType="pubmed">34788233</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratedrat P., et al. , Dynamics of cytokine, SARS-CoV-2-specific IgG, and neutralizing antibody levels in COVID-19 patients treated with convalescent plasma. Diseases 11, 112 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10527804</ArticleId><ArticleId IdType="pubmed">37754308</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan K., et al. , Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. U.S.A. 117, 9490–9496 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196837</ArticleId><ArticleId IdType="pubmed">32253318</ArticleId></ArticleIdList></Reference><Reference><Citation>Perotti C., et al. , Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica 105, 2834–2840 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716363</ArticleId><ArticleId IdType="pubmed">33256382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandopadhyay P., et al. , Nature and dimensions of systemic hyperinflammation and its attenuation by convalescent plasma in severe COVID-19. J. Infect. Dis. 224, 565–574 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928875</ArticleId><ArticleId IdType="pubmed">34398242</ArticleId></ArticleIdList></Reference><Reference><Citation>Habtehyimer F., et al. , COVID-19 convalescent plasma therapy decreases inflammatory cytokines: A randomized controlled trial. Microbiol. Spectr. 12, e0328623 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10783116</ArticleId><ArticleId IdType="pubmed">38009954</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y., et al. , COVID-19 convalescent plasma composition and immunological effects in severe patients. J. Autoimmun. 118, 102598 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826092</ArticleId><ArticleId IdType="pubmed">33524876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosn L., et al. , Interleukin-6 blocking agents for treating COVID-19: A living systematic review. Cochrane Database Syst. Rev. 6, Cd013881 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10237088</ArticleId><ArticleId IdType="pubmed">37260086</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., et al. , COVID-19 convalescent plasma is more than neutralizing antibodies: A narrative review of potential beneficial and detrimental co-factors. Viruses 13, 1594 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8402718</ArticleId><ArticleId IdType="pubmed">34452459</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M., et al. , Transcriptional and proteomic insights into the host response in fatal COVID-19 cases. Proc. Natl. Acad. Sci. U.S.A. 117, 28336–28343 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668053</ArticleId><ArticleId IdType="pubmed">33082228</ArticleId></ArticleIdList></Reference><Reference><Citation>Misset B., et al. , Convalescent plasma for Covid-19-induced ARDS in mechanically ventilated patients. N. Engl. J. Med. 389, 1590–1600 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10755833</ArticleId><ArticleId IdType="pubmed">37889107</ArticleId></ArticleIdList></Reference><Reference><Citation>Dispinseri S., et al. , Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat. Commun. 12, 2670 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113594</ArticleId><ArticleId IdType="pubmed">33976165</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Vicente M., et al. , Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. J. Intern. Med. 291, 232–240 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661581</ArticleId><ArticleId IdType="pubmed">34611927</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchini M., et al. , Convalescent plasma and predictors of mortality among hospitalized patients with COVID-19: a systematic review and meta-analysis. Clin. Microbiol. Infect., 10.1016/j.cmi.2024.07.020 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2024.07.020</ArticleId><ArticleId IdType="pubmed">39067517</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchini M., Casadevall A., Dragotakes Q., Focosi D.. Avoided and avoidable deaths with the use of COVID-19 convalescent plasma in Italy during the first two years of pandemic. medRxiv [Preprint] (2024). 10.1101/2024.08.12.24311864 (Accessed 12 September 2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.08.12.24311864</ArticleId><ArticleId IdType="pmc">PMC11433499</ArticleId><ArticleId IdType="pubmed">39337989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagchi S., et al. , Rates of COVID-19 among residents and staff members in nursing homes–United States, May 25-November 22, 2020. MMWR Morb. Mortal. Wkly. Rep. 70, 52–55 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808710</ArticleId><ArticleId IdType="pubmed">33444301</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C., Counard A., Tang S., Brister N., Ezike, Notes from the field: COVID-19-associated mortality risk among long-term care facility residents and community-dwelling adults aged ≥65 years–Illinois, December 2020 and January 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 803–805 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35709016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunze K. L., et al. , Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors.Nat. Commun. 12, 4864 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357797</ArticleId><ArticleId IdType="pubmed">34381030</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., et al. , High-throughput neutralization and serology assays reveal correlated but highly variable humoral immune responses in a large population of individuals infected with SARS-CoV-2 in the US between March and August 2020. mBio, 14, e0352322 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10128039</ArticleId><ArticleId IdType="pubmed">36786604</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein S. L., et al. , Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J. Clin. Invest. 130, 6141–6150 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598041</ArticleId><ArticleId IdType="pubmed">32764200</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan D., Casadevall A., COVID-19 serology data provide guidance for future deployments of convalescent plasma. mBio 14, e0042823. (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10294630</ArticleId><ArticleId IdType="pubmed">37039667</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozaffari E., et al. , Clinical management of hospitalized coronavirus disease 2019 patients in the United States. Open Forum. Infect. Dis. 9, ofab498 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522394</ArticleId><ArticleId IdType="pubmed">34984212</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., et al. , Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24, 44–46 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088355</ArticleId><ArticleId IdType="pubmed">15616839</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko J. H., et al. , Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience. Antivir. Ther. 23, 617–622 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29923831</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung F., et al. , Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52, 447–456 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7531589</ArticleId><ArticleId IdType="pubmed">21248066</ArticleId></ArticleIdList></Reference><Reference><Citation>van Griensven J., et al. , Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374, 33–42 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856332</ArticleId><ArticleId IdType="pubmed">26735992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch E. M., et al. , The potential role of passive antibody-based therapies as treatments for monkeypox. mBio 13, e0286222 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9765457</ArticleId><ArticleId IdType="pubmed">36314809</ArticleId></ArticleIdList></Reference><Reference><Citation>Roux E., Martin L., Chaillou A., Trois cents cas de diphtérie traités par le sérum antidiphtérique. Ann. Inst. Pasteur 8, 640–661 (1894).</Citation></Reference><Reference><Citation>Luke T. C., Kilbane E. M., Jackson J. L., Hoffman S. L., Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann. Intern. Med. 145, 599–609 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16940336</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld J. W., Marks P., Casadevall A., Joyner M. J., The value of observational registry studies for the next infectious disease emergency. mBio 14, e0256523 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10746279</ArticleId><ArticleId IdType="pubmed">37937981</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripoll J. G., et al. , Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19. mBio 15, e0040024 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11078006</ArticleId><ArticleId IdType="pubmed">38602414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan D. J. Jr., Convalescent plasma and other antibody therapies for infectious diseases-lessons learned from COVID-19 and future prospects. Curr. Top. Microbiol. Immunol. (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39117846</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon H., Pirofski L.A., Generating the evidence base for convalescent plasma use for a new infectious disease. Curr. Top. Microbiol. Immunol. (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39117847</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar E., et al. , Significantly decreased mortality in a large cohort of COVID-19 patients transfused early with convalescent plasma containing high titer anti-SARS-CoV-2 spike protein IgG. Am. J. Pathol. 191, 90–107 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7609241</ArticleId><ArticleId IdType="pubmed">33157066</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak E. B., Garcia R. B., Menard J. M., Salemi J. L., Out-of-hospital COVID-19 deaths: Consequences for quality of medical care and accuracy of cause of death coding. Am. J. Public Health 111, S101–S106 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8495651</ArticleId><ArticleId IdType="pubmed">34314208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>